SG11202005944VA - Intraductal methods of treatment of breast disorders - Google Patents
Intraductal methods of treatment of breast disordersInfo
- Publication number
- SG11202005944VA SG11202005944VA SG11202005944VA SG11202005944VA SG11202005944VA SG 11202005944V A SG11202005944V A SG 11202005944VA SG 11202005944V A SG11202005944V A SG 11202005944VA SG 11202005944V A SG11202005944V A SG 11202005944VA SG 11202005944V A SG11202005944V A SG 11202005944VA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- breast disorders
- intraductal
- methods
- intraductal methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609665P | 2017-12-22 | 2017-12-22 | |
| PCT/US2018/066860 WO2019126538A1 (en) | 2017-12-22 | 2018-12-20 | Intraductal methods of treatment of breast disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005944VA true SG11202005944VA (en) | 2020-07-29 |
Family
ID=66995048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005944VA SG11202005944VA (en) | 2017-12-22 | 2018-12-20 | Intraductal methods of treatment of breast disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210000920A1 (en) |
| EP (1) | EP3727403A4 (en) |
| JP (1) | JP2021506943A (en) |
| KR (1) | KR20200103764A (en) |
| CN (1) | CN111936152A (en) |
| AU (1) | AU2018392692A1 (en) |
| CA (1) | CA3086655A1 (en) |
| IL (1) | IL275543A (en) |
| MX (1) | MX2020006654A (en) |
| RU (1) | RU2020124144A (en) |
| SG (1) | SG11202005944VA (en) |
| WO (1) | WO2019126538A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| JP2021515797A (en) * | 2018-03-15 | 2021-06-24 | アトッサ・セラピューティクス・インコーポレイテッド | Insight method for inducing immune response |
| EP3946473A4 (en) * | 2019-03-27 | 2023-07-05 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for altering macrophage phenotype |
| BR112021026334A2 (en) * | 2019-06-27 | 2022-05-10 | Medstar Health | HDac6-activated macrophages, compositions, and uses thereof |
| EP3996735A4 (en) * | 2019-07-12 | 2023-07-19 | The Research Foundation for The State University of New York | Compositions and methods to block and bind cxcr4 to modulate cellular function |
| WO2021048315A1 (en) * | 2019-09-11 | 2021-03-18 | Institut Gustave Roussy | Use of duox1 inhibitors for treating cancer |
| WO2022098540A1 (en) * | 2020-11-06 | 2022-05-12 | Purdue Research Foundation | Non-cationic soft polyphenol nanocapsules for effective systemic delivery of small interfering rna (sirna) for cancer treatment |
| JP2023549555A (en) | 2020-11-18 | 2023-11-27 | パイオニア イミュノセラピューティクス インコーポレイテッド | Anti-MARCO antibody and its use |
| CN113288871B (en) * | 2021-05-28 | 2022-09-16 | 华中科技大学 | Pharmaceutical composition liposome formulations for modulation of epigenetic and immune checkpoints |
| CN116966307A (en) * | 2022-04-22 | 2023-10-31 | 深圳先进技术研究院 | Application of AMPK inhibitor combined with HDAC inhibitor in preparation of medicines for treating tumors |
| WO2024073600A1 (en) * | 2022-09-28 | 2024-04-04 | Board Of Regents, The University Of Texas System | Compositions and methods for marco inhibition and improved drug delivery |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| US8709379B2 (en) * | 2006-03-29 | 2014-04-29 | Scitech Development, Llc | Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| WO2014072441A1 (en) * | 2012-11-09 | 2014-05-15 | Transgene Sa | Modulation of monocytes, or precursors thereof, differentiation |
| CN105030792B (en) * | 2015-06-30 | 2017-08-25 | 上海交通大学 | Applications of the Desogestrel in the positive breast cancer product of the negative AhRs of inhibitor against colon carcinoma cells/ER is prepared |
| US11352439B2 (en) * | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| US20180312600A1 (en) * | 2015-10-21 | 2018-11-01 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| WO2017192973A1 (en) * | 2016-05-05 | 2017-11-09 | The Board Of Regents Of The University Of Texas System | Methods of treating cancers with gpr132 inhibitors |
-
2018
- 2018-12-20 RU RU2020124144A patent/RU2020124144A/en not_active Application Discontinuation
- 2018-12-20 AU AU2018392692A patent/AU2018392692A1/en not_active Abandoned
- 2018-12-20 KR KR1020207021353A patent/KR20200103764A/en not_active Application Discontinuation
- 2018-12-20 US US16/956,949 patent/US20210000920A1/en active Pending
- 2018-12-20 CA CA3086655A patent/CA3086655A1/en active Pending
- 2018-12-20 MX MX2020006654A patent/MX2020006654A/en unknown
- 2018-12-20 JP JP2020534923A patent/JP2021506943A/en active Pending
- 2018-12-20 SG SG11202005944VA patent/SG11202005944VA/en unknown
- 2018-12-20 EP EP18893015.0A patent/EP3727403A4/en active Pending
- 2018-12-20 WO PCT/US2018/066860 patent/WO2019126538A1/en unknown
- 2018-12-20 CN CN201880088647.0A patent/CN111936152A/en active Pending
-
2020
- 2020-06-21 IL IL275543A patent/IL275543A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210000920A1 (en) | 2021-01-07 |
| KR20200103764A (en) | 2020-09-02 |
| IL275543A (en) | 2020-08-31 |
| JP2021506943A (en) | 2021-02-22 |
| WO2019126538A1 (en) | 2019-06-27 |
| CA3086655A1 (en) | 2019-06-27 |
| CN111936152A (en) | 2020-11-13 |
| MX2020006654A (en) | 2020-11-06 |
| EP3727403A1 (en) | 2020-10-28 |
| EP3727403A4 (en) | 2022-01-12 |
| RU2020124144A (en) | 2022-01-24 |
| RU2020124144A3 (en) | 2022-01-24 |
| AU2018392692A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275543A (en) | Intraductal methods of treatment of breast disorders | |
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL273693A (en) | Treatment of inflammatory disorders | |
| ZA202006746B (en) | Methods of treatment | |
| IL269082A (en) | Methods of treating lysosomal disorders | |
| IL267818A (en) | Methods for the treatment of neurological disorders | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| IL270781A (en) | Treatment of depressive disorders | |
| IL269604A (en) | Pantids for treatment of autoimmune disorders | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| IL270362B (en) | Treatment of glaucoma | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| IL263080B (en) | Treatment of neurological disorders | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| IL274132A (en) | Treatment of skin disorders | |
| GB201706823D0 (en) | Treatment of psychological disorders | |
| GB201715763D0 (en) | Treatment of neurological disease | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders | |
| GB201706662D0 (en) | Treatment of neurological diseases | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| GB201602640D0 (en) | Treatment of fibrotic disorders |